High serum GGT expression is an important prognostic factor for poor overall survival (OS) and recurrence‐free survival (RFS) in advanced hepatocellular carcinoma (HCC) patients undergoing radical hepatectomy for HCC [119], as well as in advanced hepatocellular carcinoma (HCC) patients undergoing transcatheter arterial chemoembolization (TACE) [120]. This evidence concerns the gene GGTLC3 and hepatocellular carcinoma.